Breast Cancer: New Questions About Antiresorptive Therapy; Warning About Completion ALND

PURPOSE: Medication-related osteonecrosis of the jaw (MRONJ) is one of the most important toxicities of antiresorptive therapy, which is standard practice for patients with breast cancer and bone metastases. ͏    ͏    ͏    ͏    ͏    ͏    ͏    ͏    [SYNOPSI logo] [Dr image] Rosana Gnanajothy, MD Breast Medical Oncologist Hematology Oncology Physician Wednesday, September 25, 2024 A large 20-year retrospective study in metastatic breast cancer showed real-world incidences of medication-related osteonecrosis of the jaw higher than previously reported, along with key differences between the timing of the side effect for denosumab vs bisphosphonates. Researchers are also questioning the use of completion axillary lymph node dissection as a way to identify patients who can benefit from adjuvant abemaciclib for early-stage breast cancer, based on the results of the phase III SENOMAC trial. Other noteworthy new research involves the breast cancer index; use of postoperative radiation therapy, especially in older patients; and confirmation of the benefits of annual mammography screening, regardless of age, race, or menopausal status. Journal of Clinical Oncology [Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With Breast Cancer During a 20-Year Follow-Up: A Population-Based Multicenter Retrospective Study.]( The Lancet Oncology [Completion axillary lymph node dissection for the identification of pN2-3 status as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3...]( JAMA Oncology [Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor-Positive Breast Cancer.]( The Lancet Oncology [Postoperative radiotherapy in women with early operable breast cancer (Scottish Breast Conservation Trial): 30-year update of a randomised, controlled, phase 3 trial.]( Journal of Clinical Oncology [Breast Cancer Screening Interval: Effect on Rate of Late-Stage Disease at Diagnosis and Overall Survival.]( [A Property of Everyday Health group] © 2024 Everyday Health Media, LLC. MedPage Today is among the federally registered trademarks of MedPage Today, LLC, and may not be used by third parties without explicit permission. You have received this email because you have registered to receive emails at www.medpagetoday.com, with the email address: {EMAIL} [Manage Email Preferences]( | [Unsubscribe](lst=Non Sold MPT Condition Alert_Oncology) | [Terms of Use]( | [Privacy Policy]( Technical Questions: feedback@medpagetoday.com 114 5th Avenue, 15th Floor New York, NY 10011